A detailed history of Wells Fargo & Company transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 39,184 shares of CPRX stock, worth $852,252. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,184
Previous 37,420 4.71%
Holding current value
$852,252
Previous $596,000 1.68%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$14.68 - $16.92 $25,895 - $29,846
1,764 Added 4.71%
39,184 $606,000
Q1 2024

May 10, 2024

BUY
$13.18 - $17.11 $119,634 - $155,307
9,077 Added 32.03%
37,420 $596,000
Q4 2023

Feb 09, 2024

SELL
$11.78 - $17.29 $1.12 Million - $1.64 Million
-94,680 Reduced 76.96%
28,343 $476,000
Q3 2023

Nov 13, 2023

SELL
$11.69 - $15.02 $618,588 - $794,798
-52,916 Reduced 30.08%
123,023 $1.44 Million
Q2 2023

Aug 15, 2023

BUY
$11.5 - $18.08 $469,027 - $737,392
40,785 Added 30.18%
175,939 $2.36 Million
Q1 2023

May 12, 2023

BUY
$14.34 - $21.05 $990,148 - $1.45 Million
69,048 Added 104.45%
135,154 $2.24 Million
Q4 2022

Feb 13, 2023

BUY
$12.25 - $19.5 $199,319 - $317,284
16,271 Added 32.65%
66,106 $1.23 Million
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $257,061 - $565,098
36,411 Added 271.24%
49,835 $640,000
Q2 2022

Aug 12, 2022

SELL
$6.23 - $8.57 $2.12 Million - $2.92 Million
-340,600 Reduced 96.21%
13,424 $94,000
Q1 2022

May 16, 2022

SELL
$5.31 - $8.31 $313,629 - $490,821
-59,064 Reduced 14.3%
354,024 $2.94 Million
Q4 2021

Feb 14, 2022

SELL
$5.21 - $7.45 $1.81 Million - $2.58 Million
-346,570 Reduced 45.62%
413,088 $2.8 Million
Q3 2021

Nov 15, 2021

SELL
$4.85 - $6.04 $103,950 - $129,455
-21,433 Reduced 2.74%
759,658 $4.03 Million
Q2 2021

Aug 16, 2021

BUY
$4.29 - $6.05 $2.83 Million - $3.99 Million
659,072 Added 540.14%
781,091 $4.49 Million
Q1 2021

May 13, 2021

SELL
$3.45 - $4.69 $394,648 - $536,493
-114,391 Reduced 48.39%
122,019 $562,000
Q4 2020

Feb 09, 2021

SELL
$2.97 - $3.83 $199,797 - $257,651
-67,272 Reduced 22.15%
236,410 $790,000
Q3 2020

Nov 05, 2020

BUY
$2.97 - $5.08 $127,208 - $217,581
42,831 Added 16.42%
303,682 $902,000
Q2 2020

Aug 13, 2020

BUY
$3.48 - $5.05 $122,092 - $177,174
35,084 Added 15.54%
260,851 $1.21 Million
Q1 2020

May 14, 2020

BUY
$2.61 - $5.21 $589,251 - $1.18 Million
225,767 New
225,767 $869,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.24B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.